-
Medigene Files Patent for Unique NK-Specific TCR Construct with European Patent Office
13 Mar 2025 13:30 GMT
… To enable this innovation, Medigene combined TCR-guided precision … : Business Research Insights). Medigene’s proprietary TCR-NK … NK cell-based therapies. Medigene continues to strengthen its … press release --- About Medigene AG Medigene AG (FSE: MDG1) …
-
Medigene & EpimAb ink co-development partnership for TCR-guided T Cell Engagers to treat of immune-related disorders
01 Mar 2025 05:46 GMT
… expertise of each company with Medigene’s 3S (sensitive, specific … said Selwyn Ho, CEO of Medigene AG. “This co-development … End-To-End Platform, Medigene discovers natural TCR sequences with … of adoptive cell therapies.
Medigene AG is an immuno-oncology …
-
Medigene and EpimAb Partner on Co-Development of TCR-Guided T Cell Engagers
28 Feb 2025 15:59 GMT
… expertise of each company with Medigene’s 3S (sensitive, specific … said Selwyn Ho, CEO of Medigene AG. “This co-development agreement … further expands the application of Medigene’s TCRs into off- … discover new TCR-TCEs with Medigene’s unique TCRs,” said …
-
Medigene and EpimAb to develop T cell engagers for solid tumours
28 Feb 2025 12:43 GMT
… and generation capabilities of Medigene and EpimAb’s cluster … between the two companies.
Medigene CEO Selwyn Ho stated: … antigen (HLA) complexes.
Medigene’s end-to-end platform … cells.
In August 2024, Medigene and global contract research, development …
-
Medigene and Epimab to codevelop TCR-guided T-cell engagers
27 Feb 2025 16:11 GMT
Immuno-oncology
Medigene AG and Epimab Biotherapeutics Inc. …
-
Medigene and EpimAb Biotherapeutics Enter into a Co-Development Partnership for TCR-Guided T Cell Engagers
27 Feb 2025 08:00 GMT
… Shanghai, February 27, 2025. Medigene AG (Medigene, FSE: MDG1, Prime … press release --- About Medigene AG Medigene AG (FSE: MDG1) … visit https://medigene.com/ About EpimAb … these forward-looking statements. Medigene® is a registered trademark …
-
Medigene's JOVI technology receives US patent
20 Feb 2025 07:51 GMT
… the official notification received by Medigene in 2025.
“We … Dolores Schendel, CSO of Medigene. “Our expertise in T … superior TCR-guided therapies.
Medigene continuously strengthens and expands … proprietary E2E Platform technologies.
Medigene AG is an immuno- …
-
Medigene AG Expands Patent Portfolio with Patent Grant for its JOVI Technology in the U.S.
19 Feb 2025 10:00 GMT
… , February 19, 2025. Medigene AG (Medigene, FSE: MDG1, Prime Standard … TCR-guided therapies. Medigene continuously strengthens and expands … press release --- About Medigene AG Medigene AG (FSE: MDG1 … these forward-looking statements. Medigene® is a registered …
-
Medigene AG announces closing of its first SEPA tranche
03 Feb 2025 17:00 GMT
… , February 3, 2025. Medigene AG (Medigene or the “Company”, FSE … press release --- About Medigene AG Medigene AG (FSE: MDG1) … actual results achieved by Medigene may differ significantly from … these forward-looking statements. Medigene® is a registered …
-
Medigene announces KRAS G12V as first target for TCR─guided T cell engagers
10 Dec 2024 12:12 GMT
… for the partnership between Medigene and WuXi Biologics, which … collaboration seeks to harness Medigene’s expertise in the … End-To-End Platform, Medigene discovers natural TCR sequences … and other challenging neoantigens.
Medigene AG is an immuno-oncology …
About
© 1995-2025